株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウイルス性結膜炎 : パイプライン製品の分析

Viral Conjunctivitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 201009
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ウイルス性結膜炎 : パイプライン製品の分析 Viral Conjunctivitis - Pipeline Review, H2 2016
出版日: 2016年08月17日 ページ情報: 英文 42 Pages
概要

ウイルス性結膜炎は、よく見られる自己限定性の疾患で、通常、アデノウイルスが原因となって引き起こされます。ウィルス性結膜炎は発病してから目の赤い間は非常に伝染しやすく、それは通常10〜12日間です。徴候は、目のかゆみ、涙目、赤目、膿、光に対する過敏症(角膜が関連)などがあります。 治療は、潤滑剤、血管収縮薬、抗ヒスタミン剤を用います。

当レポートでは、ウイルス性結膜炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ウイルス性結膜炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Adenovir Pharma AB
  • NanoViricides, Inc.
  • Panoptes Pharma Ges.m.b.H.
  • Shire Plc
  • Starpharma Holdings Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8361IDB

Summary

Global Markets Direct's, 'Viral Conjunctivitis - Pipeline Review, H2 2016', provides an overview of the Viral Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
  • The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects
  • The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Viral Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Viral Conjunctivitis - Overview
  • Viral Conjunctivitis - Therapeutics under Development by Companies
  • Viral Conjunctivitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Viral Conjunctivitis - Products under Development by Companies
  • Viral Conjunctivitis - Companies Involved in Therapeutics Development
    • Adenovir Pharma AB
    • NanoViricides, Inc.
    • Panoptes Pharma Ges.m.b.H.
    • Shire Plc
    • Starpharma Holdings Limited
  • Viral Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • APD-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-514 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EKCCide-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Viral Conjunctivitis - Dormant Projects
  • Viral Conjunctivitis - Discontinued Products
  • Viral Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
      • Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
      • Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
      • May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Viral Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2016
  • Viral Conjunctivitis - Pipeline by NanoViricides, Inc., H2 2016
  • Viral Conjunctivitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016
  • Viral Conjunctivitis - Pipeline by Shire Plc, H2 2016
  • Viral Conjunctivitis - Pipeline by Starpharma Holdings Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Viral Conjunctivitis - Dormant Projects, H2 2016
  • Viral Conjunctivitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Viral Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top